Anti-OX40 prevents effector T-cell accumulation and CD8+ T-cell mediated skin allograft rejection

Transplantation

Volumn 90, Issue 12, 2010, Pages 1265-1271

  Kinnear, Gillian ^a   Wood, Kathryn J ^a   Marshall, Diane ^b   Jones, Nick D ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UCB PHARMA   (Belgium)

Author keywords

CD8 T cells; Costimulation; Mice; OX40; Transplantation

Indexed keywords

ALLOANTIGEN; ANTIBODY; CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; OX40 ANTIBODY; T LYMPHOCYTE RECEPTOR; THYMIDINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELL COUNT; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; EFFECTOR CELL; FLOW CYTOMETRY; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN ALLOGRAFT REJECTION; SKIN TRANSPLANTATION; TRANSGENIC ANIMAL;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CELL SURVIVAL; GRAFT REJECTION; ISOANTIGENS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; RECEPTORS, OX40; SKIN TRANSPLANTATION; T-LYMPHOCYTES; THYMIDINE; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 78650852565     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181fe5396     Document Type: Article

References (47)

1. Croft M. Control of immunity by the TNFR-related molecule OX40 (CD134). Annu Rev Immunol 2010; 28: 57.
2. Calderhead DM, Buhlmann JE, van den Eertwegh AJ, et al. Cloning of mouse Ox40: A T cell activation marker that may mediate T-B cell interactions. J Immunol 1993; 151: 5261.
3. al-Shamkhani A, Birkeland ML, Puklavec M, et al OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand. Eur J Immunol. 1996, 26; 1695.
4. Miura S, Ohtani K, Numata N, et al. Molecular cloning and characterization of a novel glycoprotein, gp34, that is specifically induced by the human T-cell leukemia virus type I transactivator p40tax. Mol Cell Biol 1991; 11: 1313.
5. Baum PR, Gayle RB III, Ramsdell F, et al. Molecular characterization of murine and human OX40/OX40 ligand systems: Identification of a human OX40 ligand as the HTLV-1-regulated protein gp34. EMBO J 1994; 13: 3992.
6. Stüber E, Neurath M, Calderhead D, et al. Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. Immunity 1995; 2: 507.
7. Stüber E, Strober W. The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response. J Exp Med 1996; 183: 979.
8. Ohshima Y, Tanaka Y, Tozawa H, et al. Expression and function of OX40 ligand on human dendritic cells. J Immunol 1997; 159: 3838.
9. Brocker T, Gulbranson-Judge A, Flynn S, et al. CD4 T cell traffic control: In vivo evidence that ligation of OX40 on CD4 T cells by OX40- ligand expressed on dendritic cells leads to the accumulation of CD4 T cells in B follicles. Eur J Immunol 1999; 29: 1610.
10. Imura A, Hori T, Imada K, et al. The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells. J Exp Med 1996; 183: 2185.
11. Rogers PR, Song J, Gramaglia I, et al. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 2001; 15: 445.
12. Flynn S, Toellner KM, Raykundalia C, et al. CD4 T cell cytokine differentiation: The B cell activation molecule, OX40 ligand, instructs CD4 T cells to express interleukin 4 and upregulates expression of the chemokine receptor, Blr-1. J Exp Med 1998; 188: 297.
13. Vu MD, Clarkson MR, Yagita H, et al. Critical, but conditional, role of OX40 in memory T cell-mediated rejection. J Immunol 2006; 176: 1394.
14. Bansal-Pakala P, Jember AG, Croft M. Signaling through OX40 (CD134) breaks peripheral T-cell tolerance. Nat Med 2001; 7: 907.
15. Murata K, Nose M, Ndhlovu LC, et al. Constitutive OX40/OX40 ligand interaction induces autoimmune-like diseases. J Immunol 2002; 169: 4628.
16. Pippig SD, Peña-Rossi C, Long J, et al. Robust B cell immunity but impaired T cell proliferation in the absence of CD134 (OX40). J Immunol 1999; 163: 6520.
17. Bansal-Pakala P, Halteman BS, ChengMH,et al. Costimulation of CD8 T cell responses by OX40. J Immunol 2004; 172: 4821.
18. Carboni S, Aboul-Enein F, Waltzinger C, et al. CD134 plays a crucial role in the pathogenesis of EAE and is upregulated in the CNS of patients with multiple sclerosis. J Neuroimmunol 2003; 145: 1.
19. Higgins LM, McDonald SA, Whittle N, et al. Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: Amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein. J Immunol 1999; 162: 486.
20. Stüber E, Büschenfeld A, Lüttges J, et al. The expression of OX40 in immunologically mediated diseases of the gastrointestinal tract (celiac disease, Crohn's disease, ulcerative colitis). Eur J Clin Invest 2000; 30: 594.
21. Yoshioka T, Nakajima A, Akiba H, et al. Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis. Eur J Immunol 2000; 30: 2815.
22. Martin-Orozco N, Chen Z, Poirot L, et al. Paradoxical dampening of anti-islet self-reactivity but promotion of diabetes by OX40 ligand. J Immunol 2003; 171: 6954.
23. Jones ND, Carvalho-Gaspar M, Luo S, et al. Effector and memory CD8- T cells can be generated in response to alloantigen independently of CD4- T cell help. J Immunol 2006; 176: 2316.
24. Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005; 23: 23.
25. Hancock WW, Sayegh MH, Zheng XG, et al. Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. Proc Natl Acad Sci USA 1996; 93: 13967.
26. Turka LA, Linsley PS, Lin H, et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 1992; 89: 11102.
27. Lenschow DJ, Zeng Y, Thistlethwaite JR, et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science 1992; 257: 789.
28. Iwakoshi NN, Mordes JP, Markees TG, et al. Treatment of allograft recipients with donor-specific transfusion and anti-CD154 antibody leads to deletion of alloreactive CD8- T cells and prolonged graft survival in a CTLA4-dependent manner. J Immunol 2000; 164: 512.
29. Vu MD, Amanullah F, Li Y, et al. Different costimulatory and growth factor requirements for CD4- and CD8- T cell-mediated rejection. J Immunol 2004; 173: 214.
30. Kirk AD, Burkly LC, Batty DS, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999; 5: 686.
31. van Maurik A, Wood KJ, Jones ND. Impact of both donor and recipient strains on cardiac allograft survival after blockade of the CD40-CD154 costimulatory pathway. Transplantation 2002; 74: 740.
32. Williams MA, Trambley J, Ha J, et al. Genetic characterization of strain differences in the ability to mediate CD40/CD28-independent rejection of skin allografts. J Immunol 2000; 165: 6849.
33. van Maurik A, Herber M, Wood KJ, et al. Cutting edge: CD4-CD25- alloantigen-specific immunoregulatory cells that can prevent CD8- T cell-mediated graft rejection: Implications for anti-CD154 immunotherapy. J Immunol 2002; 169: 5401.
34. Gramaglia I, Jember A, Pippig SD, et al. The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J Immunol 2000; 165: 3043.
35. Kaleeba JA, Offner H, Vandenbark AA, et al. The OX-40 receptor provides a potent co-stimulatory signal capable of inducing encephalitogenicity in myelin-specific CD4- T cells. Int Immunol 1998; 10: 453.
36. Tsukada N, Akiba H, Kobata T, et al. Blockade of CD134 (OX40)- CD134L interaction ameliorates lethal acute graft-versus-host disease in a murine model of allogeneic bone marrow transplantation. Blood 2000; 95: 2434.
37. Weinberg AD, Wallin JJ, Jones RE, et al. Target organ-specific upregulation of the MRC OX-40 marker and selective production of Th1 lymphokine mRNA by encephalitogenic T helper cells isolated from the spinal cord of rats with experimental autoimmune encephalomyelitis. J Immunol 1994; 152: 4712.
38. Curry AJ, Chikwe J, Smith XG, et al. OX40 (CD134) blockade inhibits the co-stimulatory cascade and promotes heart allograft survival. Transplantation 2004; 78: 807.
39. Demirci G, Amanullah F, Kewalaramani R, et al. Critical role of OX40 in CD28 and CD154-independent rejection. J Immunol 2004; 172: 1691.
40. Chen M, Xiao X, Demirci G, et al. OX40 controls islet allograft tolerance in CD154 deficient mice by regulating FOXP3- Tregs. Transplantation 2008; 85: 1659.
41. Yuan X, Salama AD, Dong V, et al. The role of the CD134-CD134 ligand costimulatory pathway in alloimmune responses in vivo. J Immunol 2003; 170: 2949.
42. Song A, Tang X, Harms KM, et al. OX40 and Bcl-xL promote the persistence of CD8 T cells to recall tumor-associated antigen. J Immunol 2005; 175: 3534.
43. Banuelos SJ, Markees TG, Phillips NE, et al. Regulation of skin and islet allograft survival in mice treated with costimulation blockade is mediated by different CD4- cell subsets and different mechanisms. Transplantation 2004; 78: 660.
44. So T, Lee SW, Croft M. Immune regulation and control of regulatory T cells by OX40 and 4-1BB. Cytokine Growth Factor Rev 2008; 19: 253.
45. Sponaas AM, Tomlinson PD, Antoniou J, et al. Induction of tolerance to self MHC class I molecules expressed under the control of milk protein or beta-globin gene promoters. Int Immunol 1994; 6: 277.
46. Billingham RE, Medawar PB. The technique of free skin grafting in mammals. J Exp Biol 1951; 28: 385.
47. Chapman AP. PEGylated antibodies and antibody fragments for improved therapy: A review. Adv Drug Deliv Rev 2002; 54: 531.